EN DE
Watch Assure Tech Hangzhou Co Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Assure Tech Hangzhou Co Ltd (688075) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Assure Tech Hangzhou Co Ltd stock ¥20.21, price ¥28.21, that is 28.4% below the price, quality 49 out of 100. Rating: overvalued. Calculated from audited financials with 17 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare CN · ISIN CNE100004ZC0

AT Assure Tech Hangzhou Co Ltd logo Some data Nov 7, 2026

Assure Tech Hangzhou Co Ltd

688075 · SHG
Expensive, weak quality

Our calculation puts a fair price 28% below what the stock costs today.

Solidly profitable · 16.2% net margin (FY2025)
Ranks above peers (8/10)
Quality 49/100
Some data
Fair value ¥20.21 · Overvalued (−28.4%)
Weak Growth (revenue 5y −17.7 %/yr in CNY)
Negative free cash flow
2.8% dividend yield · Pays more than it earns
Narrow moat 34/100 · thin data
Watch Assure Tech Hangzhou Co Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

¥118.77 ¥26.90 Fair Value ¥20.21 Nov 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.

How to read this chart

60‑month range ¥26.90 – ¥118.77 · fair‑value band ¥9.53 – ¥26.27 · the ¥28.21 price screens above the ¥20.21 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 7, 2026.

Follow Assure Tech Hangzhou Co in your weekly email

Every Wednesday you see whether Assure Tech Hangzhou Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Assure Tech (Hangzhou) Co., Ltd. engages in the research and development, production, and sale of vitro diagnostic reagents, and instruments in China. It is also involved in POCT and plastic product manufacturing; online sales; pharmaceutical sales; and medical testing.

Show moreShow less

In addition, the company offers drug of abuse, infectious disease, fertility, cardiac marker, tumor marker, allergen, and veterinary tests, as well as Biochemistry, chronic disease monitoring systems, and reader and analyzers.

Further, it offers infectious disease, fertility, fecal occult blood, and vaginal pH tests. Assure Tech (Hangzhou) Co., Ltd. was founded in 2008 and is based in Hangzhou, China

Stock analysis

Assure Tech Hangzhou Co Ltd (688075) currently trades at ¥28.21, while our model-based Fair Value estimate is ¥20.21, 28% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Asset-Based group reads highest at a median of ¥32.10 per share, and 2 of the 17 models we run sit above the ¥28.21 price.

Bear case: the DCF Models group reads lowest at ¥4.54, and 15 of the 17 models stay below the price. Data coverage for this calculation is medium.

Scenario range: ¥9.53 (bear) to ¥26.27 (bull), the price of ¥28.21 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 49/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Assure Tech Hangzhou Co Ltd reported revenue of 454M CNY in FY2025 versus 1.6B CNY in FY2021, a compound −26.9%/yr. Reported net income was 73.4M CNY in FY2025, compounding −43.9%/yr from FY2021.

Key figures

Market cap 3.6B CNY (≈ $536M) Small · P/S ratio 9.03 · Dividend yield 2.8% · Net margin −0.1% · Return on equity 0.0% · Return on assets (EBIT) 17.0% (5-year average) · Operating margin −1.1% · Revenue (TTM) 410M CNY.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 34 out of 100 (low confidence).

What moves the price

The share trades about 35% below its 52-week high and 5% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −28%, 688075 screens richer than that median.

Fair Value models

Bear ¥9.53 Fair Value ¥20.21 Bull ¥26.27
Price ¥28.21 · Downside -28.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Residual Income ¥24.34 ¥25.26 ¥26.92 74
Owner Earnings ¥4.50 ¥4.54 ¥4.60 73
EPV ¥8.49 ¥9.05 ¥9.53 70
All 17 models by family
DCF Models
Owner Earnings ¥4.50 ¥4.54 ¥4.60 73
Earnings-Based
Graham-Dodd ¥3.93 ¥27.38 ¥38.43 61
Lynch FV ¥14.15 ¥20.21 ¥26.27 59
PEG = 1.0 ¥14.15 ¥20.21 ¥26.27 55
EPV ¥8.49 ¥9.05 ¥9.53 70
Dividend Discount
Gordon GGM ¥6.37 ¥11.70 ¥16.38 65
DDM Multi-Stage ¥6.37 ¥10.58 ¥12.48 65
Multiples
P/E Multiple ¥9.53 ¥12.70 ¥15.88 63
P/S Multiple ¥7.36 ¥9.82 ¥12.27 58
P/B Multiple ¥136.01 ¥181.35 ¥226.69 55
EV/EBIT ¥10.57 ¥12.88 ¥15.19 63
EV/EBITDA ¥13.35 ¥16.58 ¥19.81 64
EV/Revenue ¥8.59 ¥10.71 ¥12.83 52
Asset-Based
NCAV (Graham) ¥21.19 ¥32.10 ¥40.13 52
Economic Profit
Residual Income ¥24.34 ¥25.26 ¥26.92 74
ROIC Compounder ¥8.49 ¥9.05 ¥9.53 68
Growth Earnings
Growth-Adj P/E ¥18.78 ¥26.83 ¥34.88 65

Open the full fair value analysis →

Quality Score breakdown

Overall quality 49/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 26
How much profit the company makes from its sales and capital
Quality Growth 35
Are margins and returns getting better?
Cashflow 4
Do the profits arrive as real cash?
Financial strength 87
Debt, balance sheet and risk of trouble
Investment 67
Does it invest with discipline instead of growing at any price?
Low Volatility 83
How calm the share price moves, does not count
Price momentum 25
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 7
Distance to the 52-week high, does not count
New shares 86
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 8/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−16.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−58.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−17.7%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+19.2%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−36.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year−38.9%
Dividend (yield on the price)2.8%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.64% → 15%

688075 screens overvalued: fair value 28% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Assure Tech Hangzhou Co Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks

Beats the industry median on 7/9 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 49 · Above median
Fair Value upside −28.4% · Above median
Profitability
Return on assets 1.3% · Above median
Net margin (12 months) 16.2% · Above median
Operating margin (12 months) −1.1% · Below median
Growth and dividend
Revenue growth (quarter YoY) 2.8% · Above median
Dividend yield (12 months) 2.8% · Top 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 0.69× · Cheapest 25%
P/S (12 months) 8.70× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)14 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 97
DIVIDEND (yield)57 · sector 22

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Incyte Corporation INCY $119.65 $199.23 +67% vs 688075
Regeneron Pharmaceuticals, Inc REGN $904.35 $1,275 +41% vs 688075
Genmab A/S GMAB kr 3,527 kr 3,999 +13% vs 688075
Samsung Biologics Co 207940 1,516,000 KRW 1,667,600 KRW +10% vs 688075
WuXi Biologics (Cayman) Inc 2269 HK$47.62 HK$52.38 +10% vs 688075
Vertex Pharmaceuticals Incorporated VRTX $547.09 $596.75 +9% vs 688075
argenx SE ARGX $927.21 $908.40 −2% vs 688075
CSL Limited CSL A$202.04 A$183.04 −9% vs 688075
Celltrion, Inc 068270 211,000 KRW 74,945 KRW −64% vs 688075
Royalty Pharma plc RPRX $67.30 $19.01 −72% vs 688075

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Assure Tech Hangzhou Co Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Assure Tech Hangzhou Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/688075

Frequently asked questions

Is Assure Tech Hangzhou Co Ltd (688075) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of ¥20.21 versus a price of ¥28.21, about 28% lower (overvalued).
What is the fair value of 688075?
Our model-based fair value for Assure Tech Hangzhou Co Ltd is ¥20.21 (as of Nov 7, 2026), built from audited fundamentals. The current price: ¥28.21.
What is the quality score of 688075?
Assure Tech Hangzhou Co Ltd has a Quality Score of 49/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Assure Tech Hangzhou Co Ltd (688075)?
Our model-based price target is the fair value of ¥20.21 (as of Nov 7, 2026) from 17 valuation models. Cautious scenario ¥9.53, optimistic scenario ¥26.27. It is a calculation from audited fundamentals, not an analyst target.
What is the Assure Tech Hangzhou Co Ltd stock forecast for 2026?
Our models put fair value at ¥20.21, about 28% lower versus a price of ¥28.21 (overvalued). Cautious scenario ¥9.53, optimistic scenario ¥26.27. The calculation is refreshed regularly with new filings.
What is the revenue of Assure Tech Hangzhou Co Ltd (688075)?
Assure Tech Hangzhou Co Ltd reported trailing-twelve-month revenue of about 410M CNY (latest available figure, as of Nov 7, 2026).
Does Assure Tech Hangzhou Co Ltd pay a dividend?
Assure Tech Hangzhou Co Ltd currently shows a dividend yield of 2.84% relative to its recent price (as of Nov 7, 2026).
How much is the dividend of Assure Tech Hangzhou Co Ltd (688075) and when is the ex-dividend date?
Assure Tech Hangzhou Co Ltd pays a dividend of ¥0.8 per share a year, a dividend yield of 2.8%. The last ex-dividend date was Jul 9, 2026. A dividend has been paid every year since at least 2022. The payout ratio is 139% of earnings. Our assessment: Pays more than it earns. The company pays out more in dividends than it earns, and free cash flow clearly does not cover the dividend either. It may need to be cut unless profits recover.
What is the intrinsic value of Assure Tech Hangzhou Co Ltd (688075)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Assure Tech Hangzhou Co Ltd it is ¥20.21 per share (as of Nov 7, 2026), against a price of ¥28.21. It is the blended result of 17 valuation models in 7 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Assure Tech Hangzhou Co Ltd stock overvalued or undervalued in 2026?
As of Nov 7, 2026, 688075 trades above its calculated fair value: price ¥28.21, fair value ¥20.21, a gap of about −28% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 688075?
No. The price is what the market pays today (¥28.21); the fair value is what the company's own numbers justify (¥20.21). For Assure Tech Hangzhou Co Ltd the two are ¥8.00 per share apart. That gap is exactly why we show both numbers side by side.
How much is Assure Tech Hangzhou Co Ltd worth?
The market values Assure Tech Hangzhou Co Ltd at about 3.6B CNY (market capitalisation, as of Nov 7, 2026). Per share that is ¥28.21; our models calculate a fair value of ¥20.21 per share.
What do the bullish and bearish scenarios say about 688075?
Our models span a range for Assure Tech Hangzhou Co Ltd: cautious scenario ¥9.53, base ¥20.21, optimistic ¥26.27 per share (as of Nov 7, 2026, price ¥28.21). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Assure Tech Hangzhou Co Ltd (688075)?
Balance-sheet figures for Assure Tech Hangzhou Co Ltd (as of Nov 7, 2026): return on equity 0.0%. They feed the Quality Score of 49/100, which measures business quality independently of the share price.
How far is 688075 from its 52-week high?
Assure Tech Hangzhou Co Ltd trades at ¥28.21, about 35% below its 52-week high of ¥43.24 and 5% above the low of ¥26.90 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of ¥20.21 is for.
Which stocks are comparable to Assure Tech Hangzhou Co Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Assure Tech Hangzhou Co Ltd stock attractive at the current price?
The data as of Nov 7, 2026: price ¥28.21, calculated fair value ¥20.21 (−28%), Quality Score 49/100, from 17 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 688075 calculated?
We run Assure Tech Hangzhou Co Ltd through 17 models from 7 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ¥20.21 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Assure Tech Hangzhou Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Assure Tech Hangzhou Co Ltd (688075)?
The closing price on Nov 6, 2026 was ¥28.21. Our model-based fair value is ¥20.21, about 28% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Assure Tech Hangzhou Co Ltd right now?
The price sits above even our optimistic bull case (¥26.27). The favourable scenario is already priced in. Weak quality (49/100) and above fair value at the same time, the margin of safety is missing on both counts. The model range is unusually wide (¥9.53 to ¥26.27). The outcome hinges heavily on assumptions, so read the point estimate with caution.

Key figures of Assure Tech Hangzhou Co Ltd

How large is the market capitalisation of Assure Tech Hangzhou Co Ltd (688075)?
The market capitalisation of Assure Tech Hangzhou Co Ltd is 3.6B CNY (≈ $536M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Assure Tech Hangzhou Co Ltd (688075)?
The price-to-sales ratio of Assure Tech Hangzhou Co Ltd is 9.03 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Assure Tech Hangzhou Co Ltd (688075)?
The dividend yield of Assure Tech Hangzhou Co Ltd is 2.8%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Assure Tech Hangzhou Co Ltd (688075)?
The net margin of Assure Tech Hangzhou Co Ltd is −0.1% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Assure Tech Hangzhou Co Ltd (688075)?
The return on equity (ROE) of Assure Tech Hangzhou Co Ltd is 0.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Assure Tech Hangzhou Co Ltd (688075)?
On an EBIT basis the return on assets of Assure Tech Hangzhou Co Ltd is 17.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Assure Tech Hangzhou Co Ltd (688075)?
The operating margin of Assure Tech Hangzhou Co Ltd is −1.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Assure Tech Hangzhou Co Ltd (688075)?
Revenue at Assure Tech Hangzhou Co Ltd is growing +2.8% versus a year earlier (3y avg −58.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Assure Tech Hangzhou Co Ltd (688075)?
Earnings per share at Assure Tech Hangzhou Co Ltd are growing −83.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Assure Tech Hangzhou Co Ltd (688075) generate?
The free cash flow of Assure Tech Hangzhou Co Ltd is −105M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Assure Tech Hangzhou Co Ltd (688075) hold?
Assure Tech Hangzhou Co Ltd holds more cash than debt, 463M CNY net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Assure Tech Hangzhou Co Ltd in the live analysis

One click puts Assure Tech Hangzhou Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.